Residual Dyspnea May Predict Small Airways Dysfunction and Poor Responsiveness to Single-Inhaler Triple Therapy in Asthmatic Patients
Authors:
- Keima ItoKIKeima Ito
- Tomoko TajiriTTTomoko Tajiri
- Hirono NishiyamaHNHirono Nishiyama
- Ryota KurokawaRKRyota Kurokawa
- Jenifer Maries Go YapJYJenifer Maries Go Yap
- Norihisa TakedaNTNorihisa Takeda
- Kensuke FukumitsuKFKensuke Fukumitsu
- Yoshihiro KanemitsuYKYoshihiro Kanemitsu
- Satoshi FukudaSFSatoshi Fukuda
- Takehiro UemuraTUTakehiro Uemura
- Hirotsugu OhkuboHOHirotsugu Ohkubo
- Ken MaenoKMKen Maeno
Open Access
- 1 November 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 1561-1568
Abstract
Purpose: Recently, single-inhaler triple therapy (SITT) has demonstrated efficacy in patients with uncontrolled asthma who were symptomatic despite treatment with inhaled corticosteroids/long-acting β 2 agonists. However, the characteristics of patients who benefit from SITT remain unclear in the real-world. The aim of this study was to examine the predictors of responsiveness to SITT in patients with asthma. Patients and Methods: A total of 45 patients with asthma who had regularly visited our respiratory clinic and were started on SITT from March 2019 to March 2021 were retrospectively analyzed. Patients’ demographic characteristics, residual respiratory symptoms, type 2 biomarkers, and lung function before SITT were assessed from the patients’ medical records. Predictors of responsiveness to four-week SITT were evaluated in these patients. The definition of responders was based on the physician-assessed global evaluation of treatment effectiveness. Results: Thirty-four (75%) of 45 patients were identified as responders to SITT. Non-responders showed significantly lower forced vital capacity (FVC) (%predicted) values, and complained of dyspnea more frequently than responders before SITT (p = 0.01 and p = 0.02, respectively). There were no significant differences in demographic characteristics and type 2 biomarkers between responders and non-responders. Clinical predictors of poor response to SITT were residual dyspnea (OR = 0.14, p = 0.02), low FVC (%predicted) values (OR = 1.05, p = 0.01), and FVC (%predicted) < 80% (OR = 0.11, p = 0.02). Multivariate analysis showed that poor response to SITT was associated with residual dyspnea before SITT (OR = 0.14, p = 0.02). On the other hand, patients with residual dyspnea had significantly lower FEF25– 75 (%predicted) values than patients without residual dyspnea before SITT (p = 0.04). Conclusion: Residual dyspnea, reflecting small airways dysfunction, may predict poor responsiveness to short-term SITT in patients with asthma.Keywords
This publication has 42 references indexed in Scilit:
- Tiotropium in Asthma Poorly Controlled with Standard Combination TherapyNew England Journal of Medicine, 2012
- An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F e NO) for Clinical ApplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Inhaler mishandling remains common in real life and is associated with reduced disease controlRespiratory Medicine, 2011
- Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthmaAllergy, 2011
- Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2010
- Heterogeneity of asthma according to blood inflammatory patternsThorax, 2009
- Development and validation of a cough and sputum assessment questionnaireRespiratory Medicine, 2008
- General considerations for lung function testingEuropean Respiratory Journal, 2005
- Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)Thorax, 2003
- A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory QuestionnaireAmerican Review of Respiratory Disease, 1992